December 14, 2015. The very small chance of any potential benefit and the high cost of preventing one cardiovascular event lead us to conclude that ezetimibe is not the cure most patients desire.
Read More »On Medical Treatments & Products
NCHR Testimony at FDA on Drisapersen for Duchenne Muscular Dystrophy
November 24, 2015. Drisapersen is a drug being studied for Duchenne muscular dystrophy. However, a recent large, phase 3 clinical trial did not find that it was effective at helping patients walk further.
Read More »NCHR Testimony at FDA on Sugammadex
November 6, 2016. Since sugammadex has the ability to quickly reverse the paralysis induced by neuromuscular blockers like rocuronium, it represents an innovative new option to improve surgical recovery. However, as with every new drug, we need to be certain the benefits outweigh the harms.
Read More »NCHR Testimony at FDA Advisory Committee on Cholesterol Drug Alirocumab
June 9, 2015. We are asking you to reject approval of this drug for women and people of color until and unless subgroup analyses indicate the benefits outweigh the risks for those populations.
Read More »NCHR Testimony Before FDA Advisory Panel on Flibanserin
June 4, 2015. The Center strongly supports research to advance understanding of, and solutions to, women’s lack of sexual desire. We understand that it is a real and distressing problem for many women. We have followed the regulatory history of flibanserin. Based on our analysis of the study results available today, we conclude that the benefits of this drug do not outweigh the risks. We ask the Advisory Committee to vote against approval of this drug.
Read More »